Even when it's giving out money, HEW can't escape controversy.
No one in the medical community argues that the federal government's kidney disease program isn't worthwhile. But the providers of kidney treatment are giving the Health Care Financing Administration a hard time on the issue of federal reimbursement. The agency is moving slowly, because a misstep in the kidney program could endanger the prospects for broader health insurance proposals.